Lung Cancer

Post-operative radiotherapy was associated with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non-small cell lung cancer and therefore cannot be recommended as a standard of care.

Sotorasib showed promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation.

Cemiplimab-rwlc (Libtayo) monotherapy led to a significant improvement in overall survival and progression-free survival in patients with advanced non-small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells.

Based on these data, researchers indicated that adjuvant osimertinib would be an effective and practice-changing treatment in this setting.

Apatinib in combination with gefitinib in the first-line setting demonstrated superior progression-free survival (PFS) in patients with advanced EGFR-mutant non–small cell lung cancer.

First-line treatment with the third-generation ALK TKI was also associated with higher overall and intracranial response rates in patients with ALK-positive non–small cell lung cancer.

Capmatinib (Tabrecta) demonstrated substantial antitumor activity in patients with advanced non-small cell lung cancer with a MET exon 14 skipping mutation, especially in those not treated previously.

The approval was based on results from the phase 1/2 ARROW clinical trial, which demonstrated efficacy for pralsetinib in patients with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement.

The model was found to be superior to the United States Preventive Services Task Force (USPSTF) criteria at identifying African American ever-smokers for lung cancer screening.

Results from this trial observed in patients with RET-altered lung and thyroid cancers also led to the approval of selpercatinib by the FDA in May for this indication.

The new drug application was based on results from the pivotal ongoing, single-arm, phase 2 VISION study evaluating tepotinib monotherapy in patients with advanced NSCLC with METex14 skipping alterations.

The FDA approved a generic form of pemetrexed for injection as a single-agent in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not progressed after 4 cycles of first-line platinum-based chemotherapy.

Early interim data from the registrational phase 2 TRIDENT-1 study of repotrectinib was reported by Turning Point Therapeutics, as well as regulatory feedback from the FDA regarding the TRIDENT-1 trial design.

These findings suggest that the current lung cancer screening guidelines undercount African Americans and should therefore be modified to avoid worsening the observed disparities between white and African American ever-smokers in lung cancer outcomes.

If approved, durvalumab could be administered intravenously every 4 weeks at a fixed dose of 1500 mg in unresectable stage III NSCLC after chemoradiation therapy and in previously treated advanced bladder cancer.

The FDA granted priority review to the new drug application for trilaciclib for patients with small cell lung cancer being treated with chemotherapy.

The GioTag study demonstrated that sequential afatinib and osimertinib improved overall survival among patients from the US with epidermal growth factor receptor mutation-positive non-small cell lung cancer and a T790M resistance mutation.

Data from the phase 3 CheckMate-743 trial showed a statistically significant overall survival benefit for patients with previously untreated, unresectable malignant pleural mesothelioma when treated with nivolumab plus ipilimumab.

The FDA approved Guardant360 CDx, the first liquid biopsy companion diagnostic that also uses next-generation sequencing technology to identify patients with any solid malignant neoplasm.

Pfizer Inc.’s phase 3 CROWN trial examining lorlatinib to treat patients with ALK-positive NSCLC met its primary end point of improving progression-free survival when compared to crizotinib.

Researchers suggested that based on their findings, increased efforts are needed to implement intervention strategies tailored to local settings to effectively decrease the global lung cancer burden and reduce health inequality.

This study created and assessed a parsimonious radiomic model that was able to identify a vulnerable subset of screen-detected lung cancers that are associated with poor outcome.

The FDA granted breakthrough therapy designation to osimertinib for the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.

The study is evaluating poziotinib in patients who were previously treated for non-small cell lung cancer with HER2 exon 20 insertion mutations.

Though a significant shift in coverage frameworks was detected in this study, future research should continue to monitor coverage and its possible impact on test utilization.